Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTOR NASDAQ:INCR NASDAQ:KALA NASDAQ:TCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$0.56+5.2%$0.70$0.49▼$2.33$52.44M3.47170,658 shs11,409 shsINCRInterCure$0.97+10.4%$0.98$0.68▼$1.77$52.93M1.3949,922 shs4,302 shsKALAKALA BIO$0.70+4.0%$1.93$0.59▼$1,030.00$13.54M-2.35130,263 shs43,204 shsTCRXTScan Therapeutics$0.77+3.8%$0.96$0.73▼$2.57$50.52M1.04725,204 shs294,838 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology-0.94%-6.44%-22.42%-39.05%-73.97%INCRInterCure+0.54%-1.60%-12.32%+9.90%-37.71%KALAKALA BIO+2.00%-8.57%-67.78%-87.19%-99.84%TCRXTScan Therapeutics-4.19%-17.57%-24.13%-36.07%-58.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$0.56+5.2%$0.70$0.49▼$2.33$52.44M3.47170,658 shs11,409 shsINCRInterCure$0.97+10.4%$0.98$0.68▼$1.77$52.93M1.3949,922 shs4,302 shsKALAKALA BIO$0.70+4.0%$1.93$0.59▼$1,030.00$13.54M-2.35130,263 shs43,204 shsTCRXTScan Therapeutics$0.77+3.8%$0.96$0.73▼$2.57$50.52M1.04725,204 shs294,838 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology-0.94%-6.44%-22.42%-39.05%-73.97%INCRInterCure+0.54%-1.60%-12.32%+9.90%-37.71%KALAKALA BIO+2.00%-8.57%-67.78%-87.19%-99.84%TCRXTScan Therapeutics-4.19%-17.57%-24.13%-36.07%-58.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTORCitius Oncology 2.33Hold$6.00963.83% UpsideINCRInterCure 1.00SellN/AN/AKALAKALA BIO 2.00Hold$1,158.33165,376.19% UpsideTCRXTScan Therapeutics 2.33Hold$6.00679.22% UpsideCurrent Analyst Ratings BreakdownLatest KALA, TCRX, CTOR, and INCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2026CTORCitius Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/17/2026TCRXTScan Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/14/2026CTORCitius Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/9/2026INCRInterCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/30/2026CTORCitius Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026INCRInterCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/24/2026KALAKALA BIO Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/23/2026TCRXTScan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$5.006/23/2026TCRXTScan Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.006/16/2026CTORCitius Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTORCitius OncologyN/AN/AN/AN/A$0.54 per shareN/AINCRInterCure$78.47M0.67N/AN/A$2.11 per share0.46KALAKALA BION/AN/AN/AN/A$12.56 per shareN/ATCRXTScan Therapeutics$10.32M4.88N/AN/A$2.16 per share0.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTORCitius Oncology-$24.76M-$0.47N/AN/AN/AN/A-99.47%-42.16%8/18/2026 (Estimated)INCRInterCure-$10.37M$0.0332.27N/AN/AN/AN/AN/A7/30/2026 (Estimated)KALAKALA BIO-$26.98M-$96.14N/AN/AN/AN/A-1,336.10%-94.85%8/6/2026 (Estimated)TCRXTScan Therapeutics-$129.77M-$0.96N/AN/AN/A-1,360.61%-91.94%-50.15%8/11/2026 (Estimated)Latest KALA, TCRX, CTOR, and INCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2026Q3 2026CTORCitius Oncology-$0.04N/AN/AN/A$5.83 millionN/A8/11/2026Q2 2026TCRXTScan Therapeutics-$0.29N/AN/AN/A$1.88 millionN/A8/6/2026Q2 2026KALAKALA BIO-$6.00N/AN/AN/AN/AN/A5/15/2026Q2 2026CTORCitius Oncology-$0.01-$0.27-$0.26-$0.27$7.00 million$1.67 million5/15/2026Q1 2026KALAKALA BIO-$8.50-$0.14+$8.36-$0.14N/AN/A5/6/2026Q1 2026TCRXTScan Therapeutics-$0.22-$0.22N/A-$0.22$2.50 million$0.98 million4/30/2026Q4 2025INCRInterCureN/A-$0.10N/A-$0.10N/A$23.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTORCitius OncologyN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTORCitius Oncology0.110.500.12INCRInterCure0.201.480.97KALAKALA BION/A7.917.91TCRXTScan Therapeutics0.346.656.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTORCitius Oncology70.52%INCRInterCure8.34%KALAKALA BIO24.61%TCRXTScan Therapeutics82.83%Insider OwnershipCompanyInsider OwnershipCTORCitius Oncology9.80%INCRInterCure0.24%KALAKALA BIO2.24%TCRXTScan Therapeutics6.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTORCitius OncologyN/A92.98 million83.87 millionN/AINCRInterCure35054.68 million54.55 millionOptionableKALAKALA BIO3019.34 million18.91 millionNot OptionableTCRXTScan Therapeutics10065.35 million61.27 millionNot OptionableKALA, TCRX, CTOR, and INCR HeadlinesRecent News About These CompaniesShort Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Expands By 95.5%July 30 at 5:59 AM | marketbeat.comTScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme MalignanciesJuly 29 at 7:00 AM | globenewswire.comCritical Comparison: Seres Therapeutics (NASDAQ:MCRB) versus TScan Therapeutics (NASDAQ:TCRX)July 20, 2026 | americanbankingnews.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by BrokeragesJuly 19, 2026 | americanbankingnews.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Rating of "Hold" from AnalystsJuly 19, 2026 | marketbeat.comTScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceJune 24, 2026 | globenewswire.comTScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...June 23, 2026 | markets.businessinsider.comTScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell TransplantationJune 22, 2026 | globenewswire.comCellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic MalignanciesJune 3, 2026 | businesswire.comTScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net LossJune 2, 2026 | insidermonkey.comTScan Therapeutics Expands Authorized Shares After Stockholder VoteMay 22, 2026 | tipranks.comTScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comTScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual MeetingApril 27, 2026 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 7.40%April 18, 2026 | aaii.comATScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | globenewswire.comTScan Therapeutics Consolidates Finance Leadership After Officer ResignationApril 2, 2026 | tipranks.comStrong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy SpaceMarch 25, 2026 | insidermonkey.comTScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue EstimatesMarch 4, 2026 | zacks.comTScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 4, 2026 | globenewswire.comTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102 ...February 26, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026The Ugliest Stocks in the Market Just Got a Very Expensive Vote of ConfidenceBy Bridget Bennett | July 20, 2026SanDisk’s Volatility May Be Telling Bulls What They Want to HearBy Sam Quirke | July 2, 2026IQM's Nasdaq Debut Could Change the Quantum Race for D-WaveBy Nathan Reiff | July 10, 2026Is the Memory Rally Still Alive After the Semiconductor Sell-Off?By Jessica Mitacek | July 2, 2026KALA, TCRX, CTOR, and INCR Company DescriptionsCitius Oncology NASDAQ:CTOR$0.56 +0.03 (+5.17%) As of 01:14 PM Eastern This is a fair market value price provided by Massive. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.InterCure NASDAQ:INCR$0.97 +0.09 (+10.35%) As of 01:16 PM Eastern This is a fair market value price provided by Massive. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.KALA BIO NASDAQ:KALA$0.70 +0.03 (+3.95%) As of 01:11 PM Eastern This is a fair market value price provided by Massive. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.TScan Therapeutics NASDAQ:TCRX$0.77 +0.03 (+3.83%) As of 01:14 PM Eastern This is a fair market value price provided by Massive. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Powering Up: NextEra and Brookfield Build an Off-Grid Empire 2 Unique Space ETFs That Could Upend the Industry DoorDash's Drone Certification Could Reshape Its Delivery Margins Why NXP Semiconductors Could Be the AI Stock Everyone Is Missing Palantir’s Earnings Setup Puts Its AI Growth Story Back on Trial Again Circle’s IBM Patent Deal Could Redraw the Stablecoin Infrastructure Race Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
